MedTrace Logo

Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

NCT02535104 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2018-06-06

No results posted yet for this study

Summary

Ranpirnase in topical formulation is an antiviral drug being evaluated for the topical treatment of anogenital warts. The aims of this study is to evaluate the efficacy and safety of a topical formulation of ranpirnase in subjects with genital warts.

Conditions

  • Condylomata Acuminata
  • Papillomavirus Infections
  • Sexually Transmitted Diseases

Interventions

DRUG

Ranpirnase

Topical application by subject

DRUG

Vehicle

Vehicle control

Sponsors & Collaborators

  • Tamir Biotechnology, Inc.

    lead INDUSTRY

Principal Investigators

  • Edgar Valdez, MD · Director - Research site

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Bolivia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02535104 on ClinicalTrials.gov